A Phase IIIB/IV Randomised Open-label Trial to Compare Dolutegravir + Pharmaco-enhanced Darunavir Versus Recommended Standard of Care Antiretroviral Regimens in Patients With HIV Infection Who Have Failed Recommended First Line Therapy.

Trial Profile

A Phase IIIB/IV Randomised Open-label Trial to Compare Dolutegravir + Pharmaco-enhanced Darunavir Versus Recommended Standard of Care Antiretroviral Regimens in Patients With HIV Infection Who Have Failed Recommended First Line Therapy.

Not yet recruiting
Phase of Trial: Phase III/IV

Latest Information Update: 06 Sep 2017

At a glance

  • Drugs Dolutegravir (Primary) ; Darunavir/ritonavir; Nucleoside reverse transcriptase inhibitors
  • Indications HIV-1 infections
  • Focus Therapeutic Use
  • Acronyms D2EFT
  • Most Recent Events

    • 30 Aug 2017 Planned End Date changed from 1 Dec 2020 to 30 Sep 2020.
    • 30 Aug 2017 Planned primary completion date changed from 1 Aug 2019 to 30 Sep 2019.
    • 30 Aug 2017 Planned initiation date changed from 1 Jul 2017 to 30 Sep 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top